Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

61.91USD
29 Sep 2016
Change (% chg)

-- (--)
Prev Close
$61.91
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,977,472
52-wk High
$64.00
52-wk Low
$47.97

MRK.N

Chart for MRK.N

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company's Pharmaceutical segment... (more)

Overall

Beta: 0.69
Market Cap(Mil.): $171,194.00
Shares Outstanding(Mil.): 2,765.21
Dividend: 0.46
Yield (%): 2.97

Financials

  MRK.N Industry Sector
P/E (TTM): 33.91 37.66 37.54
EPS (TTM): 1.83 -- --
ROI: 6.19 14.54 13.98
ROE: 11.43 15.32 14.88

EU mergers and takeovers (Sept 27)

BRUSSELS, Sept 27 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

Sep 27 2016

Bristol-Myers to test Opdivo with Nektar drug for several cancers

Bristol-Myers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers.

Sep 27 2016

Bayer raises sales targets for top-selling drugs after Monsanto deal

FRANKFURT German drugmaker Bayer said its two best-selling drugs had a higher annual peak sales potential than previously targeted, after the agreed $66 billion takeover of Monsanto stirred criticism it might neglect its pharmaceuticals business.

Sep 20 2016

UPDATE 1-Bayer raises sales targets for top-selling drugs after Monsanto deal

* Bayer shares seen 1.5 pct higher (Adds consumer care unit target, analyst comment, premarket share price)

Sep 20 2016

BRIEF-Bayer says Merck & Co integration disrupts business more than expected

* Bayer says had underestimated risk from emerging markets volatility related to purchase of merck & co consumer care business

Sep 20 2016

BRIEF-Sanofi files suit in U.S. to defend paten rights on Lantus and Lantus Solostar

* Files suit in U.S. To defend paten rights on Lantus and Lantus Solostar

Sep 19 2016

BRIEF-Merck presents new data examining durable efficacy with investigational cladribine tablets in multiple sclerosis

* Merck presents new data examining durable efficacy with investigational cladribine tablets in multiple sclerosis

Sep 16 2016

BRIEF-Merck, Pfizer say investigational Ertugliflozin met primary endpoint

* Merck and pfizer announce investigational Ertugliflozin met primary endpoint of A1C reduction when added to Sitagliptin and Metformin in people with type 2 diabetes

Sep 15 2016

BRIEF-Aralez acquires U.S., Canadian rights to Zontivity from Merck

* Aralez acquires united states and canadian rights to Zontivity from Merck

Sep 07 2016

Merck scraps development of osteoporosis drug due to stroke risk

Merck & Co Inc said it would stop developing its experimental osteoporosis drug after an independent analysis confirmed the treatment raises the risk of stroke.

Sep 02 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.